
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. is positioned for potential growth driven by faster-than-expected expansion in the spine market, increased sales in Enabling Technologies, and improved margins. The company has demonstrated impressive free cash flow (FCF) growth and an attractive FCF yield of 8%, indicating solid financial health despite current stock trading below historical valuation levels. Additionally, even with slight revenue misses in Q2 2025, the firm is expected to experience profit upside well into future years, suggesting a favorable outlook for investors.
Bears say
Globus Medical faces substantial risks that could negatively impact its financial performance, including slower growth in the spine market, revenue dis-synergies from the recent NuVasive merger, and disappointing sales in its Enabling Technologies segment. The company's outlook suggests potential revenue growth slowing to low-single digits, which would limit opportunities for margin expansion and indicate a decline in operational efficiency. Concerns over competitive dynamics, delayed product launches, and a challenging capital environment for robotic purchases further exacerbate the uncertainties surrounding Globus Medical’s financial outlook.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares